Thus, our findings in isolated SAHA-treated cardiomyocytes sustain the idea that HDAC-inhibition could support other approaches, such as SUMO-1 overexpression [11], in the treatment of heart disease associated with SERCA2 impairment. This evidence concerns the gene ATP2A2 and heart disorder.